首页> 外文期刊>The lancet oncology >Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (vol 16, pg 499, 2015)

【24h】

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (vol 16, pg 499, 2015)

机译：雷贝昔单抗与安慰剂联合二线FOLFIRI治疗转移性结直肠癌患者在贝伐单抗，奥沙利铂和氟嘧啶（RAISE）一线治疗期间或之后进展：一项随机，双盲，多中心，3期研究（第16卷，第499页，2015年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2015年第6期|共1页
作者
Tabernero J.; Takayuki Y.; Cohn A. L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (vol 16, pg 499, 2015) [J] . Tabernero J., Takayuki Y., Cohn A. L. The lancet oncology . 2015,第6期

机译：雷贝昔单抗与安慰剂联合二线FOLFIRI治疗转移性结直肠癌患者在贝伐单抗，奥沙利铂和氟嘧啶（RAISE）一线治疗期间或之后进展：一项随机，双盲，多中心，3期研究（第16卷，第499页，2015年）
3. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study) [J] . Japanese journal of clinical oncology. . 2012,第2期

机译：FOLFIRI加贝伐单抗5 mg / kg与10 mg / kg作为二线治疗的转移性结直肠癌患者在一线贝伐单抗加奥沙利铂为基础治疗失败的患者：一项随机III期研究（EAGLE研究）
4. FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Whon Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study) [J] . Yoshihiko Maehara Japanese Journal of Clinical Oncology . 2012,第2期

机译：FOLFIRI Plus贝伐单抗5 mg / kg和10 mg / kg作为转移性结直肠癌患者的二线治疗失败，这些患者一线贝伐单抗加奥沙利铂为基础的治疗均未通过：III期随机研究（EAGLE研究）
5. Rationale and design of the TRUSTY study: a randomised multicentre open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy [O] . Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, 2018

机译：TRUSTY研究的原理和设计：三氟哌啶/替匹西酯加贝伐单抗与伊立替康氟嘧啶+贝伐单抗作为二线治疗的转移性结直肠癌患者在第一期或之后进展的随机多中心II / III期开放性研究基于奥沙利铂的化疗
6. FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study) [O] . Mishima, Hideyuki, Oba, Koji, Sakamoto, Junichi, 2011

机译：FOLFIRI加贝伐珠单抗5 mg / kg和10 mg / kg作为二线治疗转移性结直肠癌患者失败，但一线贝伐单抗加奥沙利铂为基础的治疗失败：III期随机研究（EAGLE研究）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号